Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial

Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial

Abstract Background Migraine is a disabling disorder that impacts 40 million people in the US. Zavegepant is the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal-spray approved for the acute treatment of migraine with or without aura in adults. This study aimed to evaluate the...

Full description

Saved in:
Bibliographic Details
Main Authors: Lauren Powell, Fiona O’Sullivan, Pramoda Jayasinghe, Basia Rogula, Feng Dai, Jessica Cirillo, Samantha Sweeney, Lucy Abraham, Jessica Ailani
Format: Article
Language:English
Published: BMC 2025-01-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Calcitonin gene-related peptide
Randomized controlled trial
Therapeutics
Pain
Functional disability
Online Access:https://doi.org/10.1186/s10194-024-01915-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items